|Bid||4.81 x 100|
|Ask||4.88 x 300|
|Day's Range||4.81 - 4.88|
|52 Week Range||2.06 - 5.18|
|PE Ratio (TTM)||-18.09|
|Earnings Date||Aug 9, 2017 - Aug 14, 2017|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||8.00|
HACKENSACK, N.J. and PETACH TIKVA, Israel, July 25, 2017 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced that it has signed a definitive agreement with the University of California Irvine Medical Center (UCI) to enroll patients in the planned Phase 3 clinical trial of NurOwn® in amyotrophic lateral sclerosis (ALS), pending FDA and Institutional Review Board approvals. Dr. Namita Goyal has agreed to participate as Principal Investigator at UCI.
On July 21, 2017, BrainStorm (BCLI) announced that the company has received a $16 million grant from the California Institute for Regenerative Medicine (CIRM) to help fund the company’s upcoming Phase 3 clinical trial of NurOwn® in patients with amyotrophic lateral sclerosis (ALS). CIRM was established in 2004 through Proposition 71: the California Stem Cell Research and Cures Initiative. While CIRM initially concerned itself with supporting scientists who were just entering the stem cell field, the organization has recently launched CIRM 2.0, which aims to make funding available sooner for projects that are likely to bring stem cell therapies to patients with unmet medical needs (e.g., late stage clinical trials).
The grant from CIRM is a significant endorsement of the potential for Brainstorm's novel approach to treat ALS using adult stem cells. CIRM is the World's Largest Institution Dedicated to Cell Therapies. "We are honored to be awarded this CIRM grant, and appreciate the support of CIRM in the development of NurOwn," said Chaim Lebovits, President and CEO of Brainstorm.